Senescence-Associated Mitochondrial Dysfunction as a Therapeutic Target in Ovarian Cancer: Challenges and Opportunities.
Senescence-associated mitochondrial dysfunction (SAMD) links aging, metabolic reprogramming, and therapy resistance in ovarian cancer. Persistent damage to mitochondrial DNA (mtDNA), impaired mitochondrial quality control, and disrupted mitochondrial fusion and fission dynamics compromise electron transport (ET) and me...